Resources Waldenström’s macroglobulinaemia (WM)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

WM Educational materials video

Date of preparation: August 2023. 0223-BRU-PRC-097

BRUKINSA WM NICE Approval Discussion

Date of preparation: September 2022. 0922-BRU-PRC-084

Diagnosis, Clinical Features and Indications for WM Therapy

Date of preparation: November 2022. 1122-BRU-PRC-051

An In-Depth Look at the ASPEN Study – Dr Roger Owen and Dr Shirley D’Sa

Date of preparation: November 2022. 1122-BRU-PRC-100

Practical Considerations of BRUKINSA – Dr Jaimal Kothari 

Date of preparation: November 2022. 1122-BRU-PRC-102

Current Treatments: BSH Guidelines – Dr Dima El-Sharkawi

Date of preparation: November 2022. 1122-BRU-PRC-097

Welcome to “Real world experience treating WM and what’s next for CLL” – Dr Robert Mulrooney

Date of preparation: July 2023. 0723-BRU-PRC-076

Waldenström’s macroglobulinaemia/ lymphoplasmacytic lymphoma: An introduction – Prof George Follows

Date of preparation: July 2023. 0723-BRU-PRC-077

Case-based panel discussion – Dr Pam McKay

Date of preparation: July 2023. 0723-BRU-PRC-078

Case-based panel discussion – Dr Sarah Lawless

Date of preparation: July 2023. 0723-BRU-PRC-079

Case-based panel discussion – Dr Vishal Jayakar

Date of preparation: July 2023. 0723-BRU-PRC-080

Closing


Date of preparation: July 2023. 0723-BRU-PRC-082

The Changing Landscape of WM in Scotland with Dr Pam McKay

Date of preparation: November 2022. 1122-BRU-PRC-067

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

October 2023 [0823-BRU-PRC-171]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not